iCAD (ICAD:NASDAQ) Investor Relations Material

Overview

iCAD, Inc., a US-based company, is dedicated to providing cancer detection and therapy solutions to its customers. The company operates through two segments, namely, Cancer Detection and Cancer Therapy. Its breast AI suite, which consists of cancer detection, automated density assessment, and breast cancer risk assessment solutions, offers benefits for both 2D and 3D mammography. The company offers several products, including PowerLook, SecondLook, PowerLook Density Assessment, ProFound AI, ProFound AI Risk, and VeraLook. Its Xoft Axxent electronic brachytherapy systems are used for the treatment of early-stage breast, non-melanoma skin, and gynecological cancers in various medical settings. The company operates through direct sales organizations, as well as via original equipment manufacturer partners, distributors, technology platform partners, and resellers. The company was originally known as Howtek, Inc. but changed its name to iCAD, Inc. in June 2002. It was incorporated in 1984 and is headquartered in Nashua, New Hampshire. The company exports its products to Europe, Taiwan, Canada, China, and other international destinations.

Frequently Asked Questions

What is iCAD's ticker?

iCAD's ticker is ICAD

What exchange is iCAD traded on?

The company's shares trade on the NASDAQ stock exchange

Where are iCAD's headquarters?

They are based in Nashua, New Hampshire

How many employees does iCAD have?

There are 51-200 employees working at iCAD

What is iCAD's website?

It is icadmed.com

What type of sector is iCAD?

iCAD is in the Healthcare sector

What type of industry is iCAD?

iCAD is in the Healthcare Information Services industry

Who are iCAD's peers and competitors?

The following five companies are iCAD's industry peers:

- NantHealth, Inc.

- Total Brain Limited

- Veeva

- Premier

- Progyny